Taltz (ixekizumab) does suppress part of your immune system, but it’s not an immunosuppressant in the traditional sense. Unlike older drugs that dial down your entire immune response, Taltz blocks just one specific protein involved in inflammation: interleukin-17A (IL-17A). This makes it a targeted biologic rather than a broad immunosuppressant, though the distinction matters more in practice than it might sound on paper.
How Taltz Affects Your Immune System
Taltz is a lab-made antibody that latches onto IL-17A, a signaling protein your immune system uses to trigger inflammation. In conditions like psoriasis and psoriatic arthritis, your body overproduces IL-17A, which drives the red, scaly plaques on your skin or the swelling in your joints. By neutralizing that one protein, Taltz stops the inflammatory chain reaction without shutting down the rest of your immune defenses.
This is fundamentally different from conventional immunosuppressants like methotrexate or cyclosporine, which dampen the immune system across the board. The Arthritis Foundation draws this line clearly: conventional drugs suppress the overall immune system, while biologics like Taltz block specific parts of it. You still have a functioning immune system on Taltz. It’s just missing one tool from its toolkit.
That said, IL-17A isn’t useless. It plays a real role in defending against certain infections, particularly fungal ones. Blocking it does leave a gap, even if it’s a narrow one.
What Taltz Is Approved to Treat
The FDA has approved Taltz for four conditions:
- Moderate-to-severe plaque psoriasis in patients 6 years and older who need systemic therapy or phototherapy
- Active psoriatic arthritis in adults
- Ankylosing spondylitis in adults
- Non-radiographic axial spondyloarthritis with objective signs of inflammation in adults
All four conditions share a common thread: they’re driven by an overactive inflammatory response, and IL-17A is a key player in each one.
Infection Risk: What the Data Shows
Because Taltz partially suppresses immune function, infections are a real consideration. But the risk profile looks quite different from what you’d see with broader immunosuppressants.
In clinical trials involving over 2,000 patient-years of exposure in psoriatic arthritis, opportunistic infections occurred in 2.9% of patients. The most common were oral yeast infections (candidiasis), localized shingles (herpes zoster), and oral fungal infections. Yeast infections specifically showed up in about 3.2% of patients. This makes biological sense: IL-17A is one of the proteins your body relies on to keep fungal growth in check, so blocking it gives yeast a slightly easier foothold.
The reassuring part is that nearly all of these infections were mild or moderate and stayed localized. Most were oral thrush or similar surface-level fungal issues. No cases of systemic (body-wide) yeast infections were reported. The three serious yeast infections that did occur all resolved with treatment.
Screening and Precautions Before Starting
Before you begin Taltz, your doctor will test you for tuberculosis. The FDA label is specific: patients with active TB should not receive the drug, and anyone with latent TB needs to start TB treatment first. If you have a history of latent or active TB and it’s unclear whether you completed a full treatment course, preventive TB therapy should be considered before starting Taltz. Once you’re on the medication, you’ll be monitored for signs of active TB throughout treatment.
There’s also a small signal for inflammatory bowel disease. In the 12-week placebo-controlled portions of clinical trials, new or worsening Crohn’s disease occurred in 0.1% of Taltz patients and ulcerative colitis in 0.2%, compared to 0% in the placebo group. These numbers are low, but if you have a history of inflammatory bowel disease, it’s worth factoring in.
How Taltz Is Given
Taltz is a self-administered injection given under the skin. The schedule varies depending on the condition being treated.
For adult plaque psoriasis, treatment starts with a loading phase: 160 mg (two injections) at week zero, then 80 mg every two weeks through week 12. After that, you move to 80 mg once every four weeks as an ongoing maintenance dose. For psoriatic arthritis and ankylosing spondylitis, the schedule is simpler: 160 mg at the start, then 80 mg every four weeks with no loading phase. If you have psoriatic arthritis alongside moderate-to-severe plaque psoriasis, you’d follow the more intensive psoriasis loading schedule.
Children with plaque psoriasis are dosed by weight. Those over 50 kg follow a schedule similar to adults, while lighter children receive lower doses.
Targeted vs. Broad Immunosuppression
The practical takeaway is that Taltz sits in a gray area. It does suppress a piece of your immune response, and that has measurable consequences, primarily a modest bump in fungal infections. But it leaves the vast majority of your immune defenses intact. You’re not in the same category of vulnerability as someone on high-dose steroids, a calcineurin inhibitor, or chemotherapy.
If you’re filling out a medical form that asks whether you’re on an immunosuppressant, the honest answer is yes, with context. You’re on a biologic that targets one inflammatory pathway. That’s relevant for decisions about vaccines, surgical planning, and managing infections, but it doesn’t carry the same broad risk profile as drugs that suppress the immune system as a whole.